Compare

CytomX/$CTMX

1D1W1M3M6MYTD1Y5YMAX

About CytomX

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Ticker
$CTMX
Sector
Health
Primary listing
NASDAQ
Employees
69

CytomX Metrics

BasicAdvanced
$447M
-
-$0.45
2.24
-

What the Analysts think about CytomX

Analyst ratings (Buy, Hold, Sell) for CytomX stock.
Analyst projections of the future price of CytomX stock.

Bulls say / Bears say

In phase 1 metastatic colorectal cancer cohorts, Varseta-M produced confirmed response rates of 20% at 8.6 mg/kg and 32% at 10 mg/kg, with estimated median progression-free survival of 6.8 and 7.1 months. These are encouraging early signals in a heavily pre-treated population, though they still need confirmation in later-stage trials. (U.S. Securities and Exchange Commission)
CytomX reported $348 million in cash and investments at the end of Q3 2026 and expects its cash runway to extend into the second half of 2028. This gives it time to advance Varseta-M and its other programmes without an immediate funding need. (CytomX Therapeutics, Inc.)
Regeneron selected two additional collaboration targets, triggering a $37 million payment to CytomX, and may select up to six more. The expanded agreement offers potential milestone payments of up to about $4 billion, although these depend on future development and commercial progress. (CytomX Therapeutics, Inc.)
Diarrhoea remains a material safety concern for Varseta-M: the phase 1 report records grade 3 cases across its dose cohorts and serious treatment-related events including diarrhoea, dehydration, acute kidney injury and colitis. This could limit tolerable dosing or complicate use in a broader patient population. (U.S. Securities and Exchange Commission)
The key Varseta-M monotherapy update moved from the end of 2026 to January 2027, while the first potential registrational study is only planned for the first half of 2027. Dose selection and the path to later-stage proof therefore remain unresolved. (CytomX Therapeutics, Inc., CytomX Therapeutics, Inc.)
Competition in colorectal cancer ADCs is advancing: management identified AbbVie and Merck KGaA candidates in phase 3, as well as newer CDH17 ADCs. This could make it harder for Varseta-M to establish a lasting advantage, particularly if its clinical progress slows. (Stock Analysis)
Data summarised monthly by Lightyear AI. Last updated on 8 Nov 2026.

CytomX Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

CytomX Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.